BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, Tijms BM, Piersma SR, Pham TV, Bridel C, Ferri GL, Cocco C, Noli B, Worley PF, Xiao MF, Xu D, Oeckl P, Otto M, van der Flier WM, de Jong FJ, Jimenez CR, Lemstra AW, Teunissen CE. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol Neurodegener 2020;15:36. [PMID: 32552841 DOI: 10.1186/s13024-020-00388-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Bolsewig K, Hok-a-hin Y, Sepe F, Boonkamp L, Jacobs D, Bellomo G, Paoletti FP, Vanmechelen E, Teunissen C, Parnetti L, Willemse E, Platt B. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. JAD 2022. [DOI: 10.3233/jad-220318] [Reference Citation Analysis]
2 Joshi R, Salton SRJ. Neurotrophin Crosstalk in the Etiology and Treatment of Neuropsychiatric and Neurodegenerative Disease. Front Mol Neurosci 2022;15:932497. [DOI: 10.3389/fnmol.2022.932497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bousiges O, Blanc F. Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer's Disease. Int J Mol Sci 2022;23:6371. [PMID: 35742814 DOI: 10.3390/ijms23126371] [Reference Citation Analysis]
4 Peinado JR, Chaplot K, Jarvela TS, Barbieri EM, Shorter J, Lindberg I. Sequestration of TDP-43216-414 Aggregates by Cytoplasmic Expression of the proSAAS Chaperone. ACS Chem Neurosci 2022;13:1651-65. [PMID: 35549000 DOI: 10.1021/acschemneuro.2c00156] [Reference Citation Analysis]
5 Cervantes González A, Belbin O. Fluid markers of synapse degeneration in synucleinopathies. J Neural Transm (Vienna) 2022. [PMID: 35147800 DOI: 10.1007/s00702-022-02467-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Scott GD, Arnold MR, Beach TG, Gibbons CH, Kanthasamy AG, Lebovitz RM, Lemstra AW, Shaw LM, Teunissen CE, Zetterberg H, Taylor AS, Graham TC, Boeve BF, Gomperts SN, Graff-radford NR, Moussa C, Poston KL, Rosenthal LS, Sabbagh MN, Walsh RR, Weber MT, Armstrong MJ, Bang JA, Bozoki AC, Domoto-reilly K, Duda JE, Fleisher JE, Galasko DR, Galvin JE, Goldman JG, Holden SK, Honig LS, Huddleston DE, Leverenz JB, Litvan I, Manning CA, Marder KS, Pantelyat AY, Pelak VS, Scharre DW, Sha SJ, Shill HA, Mari Z, Quinn JF, Irwin DJ. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Front Neurol 2022;12:805135. [DOI: 10.3389/fneur.2021.805135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yu Z, Du M, Lu L. A Novel 16-Genes Signature Scoring System as Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma. Biomedicines 2022;10:317. [DOI: 10.3390/biomedicines10020317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Richter N, David L, Grothe MJ, Teipel S, Dietlein M, Tittgemeyer M, Neumaier B, Fink GR, Onur OA, Kukolja J. Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer’s Disease. JAD 2022. [DOI: 10.3233/jad-210261] [Reference Citation Analysis]
9 Bergström S, Öijerstedt L, Remnestål J, Olofsson J, Ullgren A, Seelaar H, van Swieten JC, Synofzik M, Sanchez-Valle R, Moreno F, Finger E, Masellis M, Tartaglia C, Vandenberghe R, Laforce R, Galimberti D, Borroni B, Butler CR, Gerhard A, Ducharme S, Rohrer JD, Månberg A, Graff C, Nilsson P; Genetic Frontotemporal Dementia Initiative (GENFI). A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Mol Neurodegener 2021;16:79. [PMID: 34838088 DOI: 10.1186/s13024-021-00499-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Quinn JP, Kandigian SE, Trombetta BA, Arnold SE, Carlyle BC. VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. Brain Commun 2021;3:fcab261. [PMID: 34778762 DOI: 10.1093/braincomms/fcab261] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S, Roeben B, Mammana A, Zimmermann M, Hauser AK, Deuschle C, Schulte C, Waniek K, Lachmann I, Sjödin S, Brinkmalm A, Blennow K, Zetterberg H, Gasser T, Parchi P. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol Commun 2021;9:175. [PMID: 34717775 DOI: 10.1186/s40478-021-01276-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
12 Lleó A, Carmona-Iragui M, Videla L, Fernández S, Benejam B, Pegueroles J, Barroeta I, Altuna M, Valldeneu S, Xiao MF, Xu D, Núñez-Llaves R, Querol-Vilaseca M, Sirisi S, Bejanin A, Iulita MF, Clarimón J, Blesa R, Worley P, Alcolea D, Fortea J, Belbin O. VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Alzheimers Res Ther 2021;13:119. [PMID: 34183050 DOI: 10.1186/s13195-021-00861-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lerche S, Sjödin S, Brinkmalm A, Blennow K, Wurster I, Roeben B, Zimmermann M, Hauser AK, Liepelt-Scarfone I, Waniek K, Lachmann I, Gasser T, Zetterberg H, Brockmann K. CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB. Mov Disord 2021. [PMID: 34180557 DOI: 10.1002/mds.28704] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
14 Jin Y, Vadukul DM, Gialama D, Ge Y, Thrush R, White JT, Aprile FA. The Diagnostic Potential of Amyloidogenic Proteins. Int J Mol Sci 2021;22:4128. [PMID: 33923609 DOI: 10.3390/ijms22084128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Combi R, Salsone M, Villa C, Ferini-Strambi L. Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. Int J Mol Sci 2021;22:3960. [PMID: 33921279 DOI: 10.3390/ijms22083960] [Reference Citation Analysis]
16 Boiten WA, van Steenoven I, Xiao M, Worley PF, Lemstra AW, Teunissen CE. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells 2020;10:E38. [PMID: 33383752 DOI: 10.3390/cells10010038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Álvarez I, Diez-Fairen M, Aguilar M, González JM, Ysamat M, Tartari JP, Carcel M, Alonso A, Brix B, Arendt P, Pastor P. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. Eur J Neurol 2021;28:1142-52. [PMID: 33236496 DOI: 10.1111/ene.14658] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
18 Chaplot K, Jarvela TS, Lindberg I. Secreted Chaperones in Neurodegeneration. Front Aging Neurosci 2020;12:268. [PMID: 33192447 DOI: 10.3389/fnagi.2020.00268] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]